KarMMa-2

Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma

Near Add Your Location

Sorting 13 by

  • Accepting patients
  • Show Principal Investigator
  • Accepting patients
  • Show Principal Investigator
  • Accepting patients
  • Show Principal Investigator
  • Accepting patients
  • Show Principal Investigator
  • Accepting patients
  • Show Principal Investigator
Alvin J. Siteman Cancer Center
Washington University Medical Campus
St. Louis, MO
  • Accepting patients
  • Show Principal Investigator
University of Nebraska Medical Center
Fred & Pamela Buffett Cancer Center
Omaha, NE
  • Accepting patients
  • Show Principal Investigator
Mount Sinai Hospital
Tisch Cancer Institute
New York, NY
  • Accepting patients
  • Show Principal Investigator
  • Accepting patients
  • Show Principal Investigator
Sarah Cannon Research Institute at Tennessee Oncology
TriStar Centennial Medical Center
Nashville, TN
  • Not currently accepting
  • Show Principal Investigator
1,347 hidden based on your filters. Show All

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.